Humacyte Q1 2023 Earnings Report $4.65 +0.01 (+0.22%) (As of 05:45 PM ET) Earnings HistoryForecast Humacyte EPS ResultsActual EPS-$0.22Consensus EPS -$0.22Beat/MissMet ExpectationsOne Year Ago EPSN/AHumacyte Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AHumacyte Announcement DetailsQuarterQ1 2023Date5/12/2023TimeN/AConference Call ResourcesPress ReleaseHUMA Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by A brand new opportunity in the stock market revealed (Ad)Today, I want to unlock a brand new opportunity in the stock market… One that has been able to pay out around 100% in 5 days or less so far on REAL money… It’s all thanks to a hidden force that drives some of the BIGGEST & most repetitive moves in stocks… I call it a Gamma Pocket…Will you be the next trader to discover the power of Gamma Pockets? Humacyte Earnings HeadlinesHumacyte's Symvess Debut: A Milestone With Lingering Concerns (Rating Downgrade)December 23 at 5:44 PM | seekingalpha.comHumacyte price target raised to $17 from $15 at BenchmarkDecember 23 at 12:41 PM | markets.businessinsider.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.December 23, 2024 | Crypto Swap Profits (Ad)HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law FirmDecember 23 at 10:27 AM | prnewswire.comInvestors in Humacyte, Inc. Should Contact The Gross Law Firm Before January 17, 2025 to ...December 23 at 6:07 AM | gurufocus.comInvestors in Humacyte, Inc. Should Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMADecember 23 at 5:45 AM | prnewswire.comSee More Humacyte Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Humacyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Humacyte and other key companies, straight to your email. Email Address About HumacyteHumacyte (NASDAQ:HUMA) engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.View Humacyte ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
